Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the official U.S. launch of Tryngolza™ (olezarsen), a novel, once-monthly RNA-targeted therapy for familial chylomicronemia syndrome (FCS). The drug enters the market at an annual list price of…
In 2025, Sanofi’s Cablivi (caplacizumab-yhdp) continues to play a pivotal role in the management of acquired thrombotic thrombocytopenic purpura (aTTP), a rare and life-threatening blood disorder. As the first FDA-approved nanobody therapy for aTTP, Cablivi…
Lybalvi (olanzapine/samidorphan), a new antipsychotic drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with schizophrenia and bipolar I disorder, has been formally launched in the U.S. recently. The…
The U.S. Food and Drug Administration (FDA) has approved a novel targeted drug, Lytgobi (Futibatinib), for the treatment of unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (iCCA) patients. This approval provides a new treatment option…
March 2025 Knight Therapeutics announced that its anti-CD19 monoclonal antibody drug Minjuvi (tafasitamab) has been officially marketed in Mexico. For the treatment of adult patients who are not candidates for autologous hematopoietic stem cell transplantation…
Migraines afflict more than one billion people worldwide, and their attacks of severe headache, light sensitivity and nausea often bring patients’ lives to a halt. In 2020, the FDA approved Nurtec ODT (rimegepant).This orally dissolvable…
In recent years, Testosterone Replacement Therapy (TRT) has become one of the hotspots in the global healthcare market as men’s health issues have become a growing concern. Among them, Nebido (Testosterone Undecanoate), as a long-acting…
The European Medicines Agency (EMA) recently approved Ontozry (cenobamato) for the treatment of refractory focal epileptic seizures in adults, providing a new therapeutic option for patients who have not responded well to traditional antiepileptic medications.…
April 12, 2025 — In a landmark advancement for rare cancer treatment, Ogsiveo® (nirogacestat) has solidified its position as the first and only FDA-approved therapy for adults with progressing desmoid tumors, a rare and often debilitating soft-tissue condition. Developed by SpringWorks Therapeutics,…
April 12, 2025 — The U.S. Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) as the first and only treatment specifically indicated for myelofibrosis (MF) patients with anemia, marking a significant advancement in managing this rare and debilitating…
On June 6, 2024, the U.S. Food and Drug Administration (FDA) granted approval for Rytelo™ (generic name: imetelstat), developed by Geron Corporation, for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes…
Recently, Qelbree has attracted a lot of attention in the pharmaceutical field.Qelbree focuses on specific attention-related conditions. The development of this drug has been a long and rigorous process, with researchers investing a great deal…
